Form 4 for ZNTL Zentalis Pharmaceuticals, Inc.
Accepted 2021-10-27 00:00:00 ET · period of report 2021-10-25 · accession 0001725160-21-000206 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-10-27 | 2021-10-25 | ZNTL | Pinto Alexis | CLO | S - Sale+OE | $77.73 | -30.0K | 6,826 | -81% | -$2.33M |
| D | 2021-10-27 | 2021-10-25 | ZNTL | Pinto Alexis | CLO | M - OptEx | $34.40 | +30.0K | 36.5K | +460% | +$1.03M |
| D | 2021-10-27 | 2021-10-25 | ZNTL | Pinto Alexis | CLO | M - OptEx | $0.00 | -30.0K | 245.0K | -11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-10-25 | S | D | 300 | $78.85 | 6,526 | D | — | — | |
| 2 | Common | Common Stock | 2021-10-25 | S | D | 8,098 | $77.27 | 26,628 | D | — | — | (F4) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $76.59 to $77.58. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2021-10-25 | S | D | 1,800 | $76.10 | 34,726 | D | — | — | (F3) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $75.57 to $76.53. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2021-10-25 | M | A | 30,000 | $34.40 | 36,526 | D | — | — | (F2) Includes 276 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on September 30, 2021. |
| 5 | Common | Common Stock | 2021-10-25 | S | D | 19,802 | $78.05 | 6,826 | D | — | — | (F5) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $77.59 to $78.44. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 6 | Derivative | Stock Option (Right to Buy) | 2021-10-25 | M | D | 30,000 | $0.00 | 245,000 | D | $34.40 · — to 2030-08-30 | 30,000 Common Stock | (F6) The options vest and become exercisable as to 25% of the total number of shares underlying the option on August 31, 2021 and as to the remaining 75% in 36 substantially equal monthly installments thereafter. |